Fulgent Genetics (FLGT) Competitors

Castle Biosciences (NASDAQ:CSTL) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking.

Do insiders and institutionals have more ownership in CSTL or FLGT?

92.6% of Castle Biosciences shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 7.2% of Castle Biosciences shares are held by insiders. Comparatively, 31.8% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has more volatility & risk, CSTL or FLGT?

Castle Biosciences has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.

Does the media prefer CSTL or FLGT?

In the previous week, Fulgent Genetics had 9 more articles in the media than Castle Biosciences. MarketBeat recorded 21 mentions for Fulgent Genetics and 12 mentions for Castle Biosciences. Castle Biosciences' average media sentiment score of 1.05 beat Fulgent Genetics' score of 0.34 indicating that Castle Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Castle Biosciences	5 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	2 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor CSTL or FLGT?

Fulgent Genetics received 154 more outperform votes than Castle Biosciences when rated by MarketBeat users. However, 64.75% of users gave Castle Biosciences an outperform vote while only 60.40% of users gave Fulgent Genetics an outperform vote.

Company	Underperform	Outperform
Castle Biosciences	Outperform Votes 90 64.75%	Underperform Votes 49 35.25%
Fulgent Genetics	Outperform Votes 244 60.40%	Underperform Votes 160 39.60%

Do analysts rate CSTL or FLGT?

Castle Biosciences currently has a consensus price target of $37.88, suggesting a potential upside of 18.40%. Fulgent Genetics has a consensus price target of $28.50, suggesting a potential upside of 56.68%. Given Fulgent Genetics' higher probable upside, analysts plainly believe Fulgent Genetics is more favorable than Castle Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Fulgent Genetics	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has better valuation and earnings, CSTL or FLGT?

Castle Biosciences has higher earnings, but lower revenue than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Castle Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$219.79M	4.08	-$57.47M	$0.20	159.96
Fulgent Genetics	$289.21M	1.92	-$167.82M	-$5.52	-3.30

Is CSTL or FLGT more profitable?

Castle Biosciences has a net margin of 1.95% compared to Fulgent Genetics' net margin of -59.39%. Castle Biosciences' return on equity of 1.47% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	1.95%	1.47%	1.27%
Fulgent Genetics	-59.39%	-1.81%	-1.66%

Summary

Castle Biosciences beats Fulgent Genetics on 12 of the 18 factors compared between the two stocks.